4.7 Article

The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway

Journal

CANCER LETTERS
Volume 371, Issue 2, Pages 251-261

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.11.035

Keywords

beta-Nitrostyrene; Breast cancer; Reactive oxygen species; MEK/ERK

Categories

Funding

  1. Kaohsiung Medical University Hospital [KMUH103-3R28, KMUH102-2T07, KMUH102-2R25]
  2. Kaohsiung Medical University [KMU-DT103010, KMU-TP103D18]
  3. National Health Research Institutes [NHRI-EX104-10212BI]
  4. Ministry of Health and Welfare (Health and welfare surcharge of tobacco products) of Taiwan [MOHW104-TDU-B-212-124-003]

Ask authors/readers for more resources

The beta-nitrostyrene family has been shown to suppress cancer cell proliferation and induce programmed cell death. However, mechanisms underlying beta-nitrostyrenes remain less evaluated. Here, we synthesized a beta-nitrostyrene derivative, CYT-Rx20, and characterized its anticancer effect and involving mechanisms in breast cancer. We found that CYT-Rx20 arrested breast cancer cells at G2/M phase and decreased cell viability by activating the caspase cascade, accompanying with increases of poly (ADP-ribose) polymerase (PARP) cleavage and gamma-H2AX expression. On the other hand, up-regulation of Beclin-1, ATG5, and LC-3 was observed in CYT-Rx20-induced autophagy, which was evidently shown by transmission electron microscopy. In addition to these, CYT-Rx20-induced breast cancer cell death, intracellular reactive oxygen species (ROS) formation and expression of phospho-ERK1/2, Beclin-1, and LC-3 were significantly reversed in the presence of N-acetyl-L-cysteine (NAC), a thiol antioxidant. Furthermore, the cytotoxicity of CYT-Rx20 was enhanced by co-treatment with the autophagy inhibitor chloroquine or bafilomycin A1, suggesting that an incomplete autophagy process could deteriorate CYT-Rx20-induced cytotoxicity. In nude mice xenograft study, CYT-Rx20 significantly reduced orthotopic tumor growth. Immunohistochemical analysis revealed elevated expression of phospho-ERK1/2 and LC-3 in tumor tissues of the mice treated with CYT-Rx20. Together, we propose that CYT-Rx20 may have potential to be further developed into a beta-nitrostyrene-based anticancer compound for the treatment of breast cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available